BioLineRx Ltd. (BLRX.TA)
ILA 5.8
(-9.38%)
ILA 5.8
(-9.38%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 50.7 Million USD | 98.5% |
| 2022 | 25.54 Million USD | 91.99% |
| 2021 | 13.3 Million USD | -47.33% |
| 2020 | 25.26 Million USD | 25.13% |
| 2019 | 20.18 Million USD | 35.37% |
| 2018 | 14.91 Million USD | 84.46% |
| 2017 | 8.08 Million USD | 106.65% |
| 2016 | 3.91 Million USD | 5.96% |
| 2015 | 3.69 Million USD | -16.09% |
| 2014 | 4.39 Million USD | -46.76% |
| 2013 | 8.26 Million USD | -11.47% |
| 2012 | 9.33 Million USD | 37.18% |
| 2011 | 6.8 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 38.54 Million USD | -23.99% |
| 2024 Q2 | 50.61 Million USD | 31.33% |
| 2023 FY | 50.7 Million USD | 98.5% |
| 2023 Q2 | 37.88 Million USD | 28.27% |
| 2023 Q1 | 29.53 Million USD | 15.62% |
| 2023 Q3 | 39.72 Million USD | 4.85% |
| 2023 Q4 | 50.7 Million USD | 27.65% |
| 2022 Q1 | 11.36 Million USD | -14.61% |
| 2022 FY | 25.54 Million USD | 91.99% |
| 2022 Q4 | 25.54 Million USD | -2.32% |
| 2022 Q3 | 26.14 Million USD | 132.02% |
| 2022 Q2 | 11.27 Million USD | -0.79% |
| 2021 Q2 | 17.43 Million USD | -8.0% |
| 2021 Q1 | 18.95 Million USD | -24.97% |
| 2021 FY | 13.3 Million USD | -47.33% |
| 2021 Q4 | 13.3 Million USD | -16.87% |
| 2021 Q3 | 16 Million USD | -8.21% |
| 2020 Q3 | 21.23 Million USD | -10.64% |
| 2020 FY | 25.26 Million USD | 25.13% |
| 2020 Q1 | 18.66 Million USD | -7.55% |
| 2020 Q4 | 25.26 Million USD | 18.98% |
| 2020 Q2 | 23.75 Million USD | 27.31% |
| 2019 Q3 | 18.02 Million USD | -10.65% |
| 2019 Q2 | 20.17 Million USD | -7.05% |
| 2019 Q1 | 21.7 Million USD | 45.56% |
| 2019 FY | 20.18 Million USD | 35.37% |
| 2019 Q4 | 20.18 Million USD | 11.98% |
| 2018 Q3 | 5.81 Million USD | -3.52% |
| 2018 Q2 | 6.02 Million USD | -14.55% |
| 2018 Q1 | 7.05 Million USD | -12.75% |
| 2018 Q4 | 14.91 Million USD | 156.44% |
| 2018 FY | 14.91 Million USD | 84.46% |
| 2017 Q2 | 5.61 Million USD | 4.0% |
| 2017 Q4 | 8.08 Million USD | 13.83% |
| 2017 Q3 | 7.1 Million USD | 26.42% |
| 2017 Q1 | 5.4 Million USD | 38.09% |
| 2017 FY | 8.08 Million USD | 106.65% |
| 2016 Q2 | 3.11 Million USD | 6.02% |
| 2016 Q3 | 3.66 Million USD | 17.72% |
| 2016 Q4 | 3.91 Million USD | 6.65% |
| 2016 Q1 | 2.93 Million USD | -20.4% |
| 2016 FY | 3.91 Million USD | 5.96% |
| 2015 Q3 | 4.36 Million USD | -33.32% |
| 2015 Q4 | 3.69 Million USD | -15.32% |
| 2015 FY | 3.69 Million USD | -16.09% |
| 2015 Q2 | 6.53 Million USD | 15.02% |
| 2015 Q1 | 5.68 Million USD | 29.21% |
| 2014 Q2 | 5.74 Million USD | -14.79% |
| 2014 Q1 | 6.74 Million USD | -18.37% |
| 2014 FY | 4.39 Million USD | -46.76% |
| 2014 Q4 | 4.39 Million USD | 7.49% |
| 2014 Q3 | 4.09 Million USD | -28.8% |
| 2013 Q1 | 10.39 Million USD | 11.39% |
| 2013 FY | 8.26 Million USD | -11.47% |
| 2013 Q4 | 8.26 Million USD | 2.51% |
| 2013 Q3 | 8.06 Million USD | 5.22% |
| 2013 Q2 | 7.66 Million USD | -26.31% |
| 2012 Q3 | 9.9 Million USD | 5.7% |
| 2012 FY | 9.33 Million USD | 37.18% |
| 2012 Q1 | 11.19 Million USD | 64.48% |
| 2012 Q2 | 9.36 Million USD | -16.32% |
| 2012 Q4 | 9.33 Million USD | -5.71% |
| 2011 Q3 | 6.68 Million USD | -3.73% |
| 2011 Q4 | 6.8 Million USD | 1.86% |
| 2011 FY | 6.8 Million USD | 0.0% |
| 2011 Q1 | 6.48 Million USD | 0.0% |
| 2011 Q2 | 6.94 Million USD | 7.02% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Matricelf Ltd | 3.7 Million ILA | -1270.324% |